Supplementary Information (doc 195K)

Supplementary Information
Nociceptin/orphanin FQ decreases glutamate transmission and blocks ethanol-induced
effects in the central amygdala of naïve and ethanol-dependent rats
Marsida Kallupi1,2, Florence P. Varodayan1, Christopher S. Oleata1, Diego Correia1,3, George
Luu1 and Marisa Roberto1*
Materials and Methods
Animals. We used adult male Wistar rats (n=68) ranging 435.2±26 g obtained from Charles
River (Raleigh, NC) and housed in a temperature- and humidity-controlled room on a 12-h
light/dark cycle (lights on at 6:00 am) with food and water available ad libitum. We conducted
all care procedures in accordance with the National Institutes of Health Guide for the Care and
Use of Laboratory Animals and with the Institutional Animal Care and Use Committee (IACUC)
policies of The Scripps Research Institute.
Slice preparation. We prepared CeA slices as previously described (Cruz et al, 2013; Cruz et al,
2012; Roberto et al, 2003; Roberto et al, 2004a; Roberto et al, 2004b; Roberto and Siggins,
2006). The rats were anesthetized with isoflurane (3%; Henry Schein, Dublin, OH) and
decapitated. We cut transverse slices 300-400 µm thick on a Leica 1000S vibratome (Campden,
Lafayette, IN), incubated them in an interface configuration for ~30 min, and then completely
submerged and continuously superfused (flow rate of 2-4 ml/min) them with warm (31o C),
equilibrated with 95% O2/5% CO2 artificial cerebrospinal fluid (aCSF) of the following
composition in mM: NaCl, 130; KCl, 3.5; NaH2PO4, 1.25; MgSO4•7H2O, 1.5; CaCl2, 2.0;
NaHCO3, 24; glucose, 10. Drugs were added to the aCSF from stock solutions to obtain known
concentrations in the superfusate.
Chronic Ethanol Treatment. We used the standard ethanol inhalation method of The Scripps
Research Institute Alcohol Research Center to induce ethanol dependence (Cruz et al, 2012;
Roberto et al, 2010b; Roberto et al, 2003; Roberto et al, 2004a; Roberto et al, 2004b; Roberto et
al, 2006; Rogers et al, 1979). Briefly, rats were housed 2-4 per cage with a 6 AM to 6 PM light
on/off cycle and with free access to food and water. Rats were placed into ethanol vapor
chambers (n=20) and were intermittently exposed (14 h on, 10 h off) to ethanol vapors for 4
weeks. On experiment days, chronic ethanol exposed rats were maintained in the ethanol vapor
chamber until preparation of the CeA slices (under ethanol-free conditions). We recorded from
slices of chronic ethanol exposed rats 2-8 h after cutting the slices, as previously described
(Roberto et al, 2004a; Roberto et al, 2004b). Naïve/control rats were exposed to air 24 h/day.
Blood alcohol level (BAL). We determined BALs of the chronic ethanol treated animals from
tail-blood samples. The target range for BALs in dependent rats during vapor exposure was 150200 mg%. Control animals were also routinely sampled to control for possible effects of
Intracellular recording of evoked responses. We recorded from CeA neurons (from the medial
subdivision of the CeA) with sharp micropipettes filled with 3M KCl using discontinuous
current-clamp mode (Cruz et al, 2013; Cruz et al, 2012; Haubensak et al, 2010; Roberto et al,
2004a; Roberto et al, 2004b). Data were acquired with an Axoclamp-2A amplifier (Axon
Instruments, Foster City, CA) and stored for later analysis using pClamp software (Axon
Instruments). We held most neurons near their resting membrane potential (RMP) and applied
hyperpolarizing and depolarizing current steps (200 pA increments, 750 msec duration) to
generate I–V curves. We evoked postsynaptic potentials (PSPs) by stimulating locally within the
CeA through a bipolar stimulating electrode and we pharmacologically isolated excitatory
postsynaptic potentials (EPSPs) by superfusing the slices with the GABAA and GABAB receptor
blockers (30 M bicuculline and 1 M [1-(S)-3,4-dichlorophenyl)ethyl]amino-2-(S)hydroxypropyl-p- benzylphosphonic acid (CGP 55845A) respectively) in the aCSF. At the end
of the recording we often superfused 30 µM DNQX and 30 µM DL-AP-5 to confirm the
glutamatergic nature of the EPSPs. To determine the synaptic response parameters for each cell,
we performed an input-output (I-O) protocol (Cruz et al, 2012; Roberto et al, 2010b; Roberto et
al, 2003; Roberto et al, 2004a), consisting of a range of five current stimulations (typically
between 50 and 250 nA) starting at the threshold current required to elicit an EPSP. From this
threshold, the stimulus strength is increased in 3-5 steps of 30-50 nA (rate of 1 pulse per 8 sec)
until the voltage required to elicit the maximum amplitude is reached. To show drug effect, we
normalized the three middle (omitting threshold and maximal) stimulus intensities of five equal
steps as 1-3X. These stimulus strengths were maintained throughout the entire duration of the
experiment. The I/O method helps minimize inter-slice variability. We quantified the synaptic
responses by calculating the EPSP amplitude with Clampfit software (Axon Instruments). We
examined paired-pulse facilitation (PPF) in each neuron using paired stimuli at 50 and 100 msec
inter-stimulus interval (Roberto et al, 2004b). The stimulus strength was adjusted such that the
amplitude of the first EPSP was 50% of maximal, determined from the I-O relationship. We
calculated the PPF ratio as the second EPSP amplitude over that of the first EPSP. All measures
were taken before drug superfusion (control), during drug superfusion (10-30 min, depending on
the drug), and following washout (20-30 min) and are expressed as mean ± SEM.
Whole-cell patch-clamp recording of spontaneous and miniature EPSCs.
We recorded from CeA neurons visualized in brain slices (300 m) using infrared differential
interference contrast (IR-DIC) optics and CCD camera (ROLERA-XR, QImaging, Surrey,
Canada) (Cruz et al, 2013; Cruz et al, 2012; Gilpin et al, 2011; Herman et al, 2013a; Herman et
al, 2013b). A w60 water immersion objective (Olympus, Center Valley, PA) was used for
identifying and approaching CeA neurons. Whole-cell voltage-clamp recordings were made with
a Multiclamp 700B amplifier (Molecular Devices, Sunnyvale, CA), low-pass filtered at 2-5kHz,
digitized (Digidata 1440A; Molecular Devices), and stored on a PC using pClamp 10 software
(Axon Instruments). All voltage-clamp experiments were performed in a gap-free acquisition
mode with a sampling rate per signal of 10 kHz. Patch pipettes (3-5MΏ) were pulled from
borosilicate glass (Warner Instruments, Hamden, CT) and filled with an internal solution
composed of in mM: K-gluconate, 145; EGTA, 0.5; MgCl2, 2; HEPES, 10; Na-ATP, 2; Na-GTP,
0.2. Glutamatergic spontaneous EPSCs (sEPSCs) were recorded in the presence of 30 M
bicuculline and 1 M CGP 55845A, and miniature EPSCs (mEPSCs) were recorded in the
presence of 1 µM tetrodotoxin (TTX). Drugs were constituted in aCSF and applied by bath
superfusion. All 35 cells were clamped at -60 mV for the duration of the recording. In all
experiments, series resistance (<10 MΏ) was continuously monitored with a 10 mV
hyperpolarizing pulse and experiments with >20% change in series resistance were not included
in the final analysis. Frequency, amplitude and kinetics of s/mEPSCs were analyzed and visually
confirmed using a semi-automated threshold-based mini detection software (Mini Analysis,
Synaptosoft Inc., Fort Lee, NJ). To accurately determine both the sEPSC and mEPSC
amplitudes, only the events that were >5 pA were accepted for analysis. The choice of this cutoff
amplitude for acceptance of s/mEPSCs was made to obtain a high signal-to-noise ratio. Averages
of s/mEPSC characteristics were based on a minimum time interval of 3-5 min and a minimum
of 50 events. All detected events were used for event frequency analysis, but superimposed
events were eliminated for amplitude and decay kinetic analysis. All data are expressed as mean
± SEM.
We purchased picrotoxin and bicuculline from Sigma (St. Louis, MO), Tetrodotoxin from
Biotum (Hayward, CA), CGP 55845A, DNQX, DL-AP5, [Nphe1]Nociceptin(1-13)NH2 and
nociceptin from Tocris (Ellisville, MO), and ethanol from Remet (La Mirada, CA). All other
chemical reagents were purchased from (Sigma-Aldrich, St. Louis, MO). DNQX and bicuculline
were dissolved in DMSO (0.01 %), and CGP 55845A, DL-AP5, [Nphe1]Nociceptin(1-13)NH2
and nociceptin were dissolved in distilled water and then added to aCSF.
Data analysis and statistics. To analyze data acquired from intracellular and whole cell
recordings, we used Clampfit 10.2 (Molecular Devices) and MiniAnalysis 5.1 software
(Synaptosoft), respectively. We used GraphPad Prism 5.0 software (GraphPad Software, San
Diego, CA) and Statistica 7 Package (StatSoft, Tulsa, OK) for all statistical analysis of results.
The s/mEPSC results were evaluated with cumulative probability analysis, and statistical
significance was determined using the Kolmogorov-Smirnov, non-parametric two-sample test
(Van der Kloot, 1991). The pooled data for each experimental condition were then analyzed by
paired t-test analyses for individual means comparisons to evaluate single drug (nociceptin and
[Nphe1]Nociceptin(1-13)NH2) effect within the same group (naïve or ethanol exposed rats) or
within-subject one-way repeated measures ANOVA to evaluate multiple drugs (nociceptin,
nociceptin + ethanol) effects. We used t-test analyses to evaluate differences in individual means
of evoked EPSPs between two treatments (e.g., when the effect of each dose of nociceptin or the
NOP receptor antagonist, [Nphe1]Nociceptin(1-13)NH2, were compared to the respective
baseline values). We also used within-subject one-way RM ANOVA to compare EPSPs in the
same group of cells (naïve vs. dependent rats) after application of different drugs (nociceptin,
nociceptin + ethanol). When appropriate, the Student Newman-Keuls post hoc test was used to
assess significance between treatments. To assess differences resulting from ethanol exposure
(naive-control vs. ethanol-dependent rats) and drug interaction between groups, we used a twoway RM ANOVA. When appropriate, the Student Newman-Keuls post hoc test was used to
assess significance between treatments. We accepted statistical significance at the p<0.05. All
averaged values are presented as mean ± SEM.
The effects of nociceptin are not cell-type dependent.
We also examined whether nociceptin effects were cell-type dependent. Thus, similar to our
recent studies with ghrelin (Cruz et al, 2013) and cannabinoids (Roberto et al, 2010a), we
classified neurons as Type A or Type B, according to the electrophysiological characteristics
(firing pattern and lack of accommodation of action potentials) described by Schiess et al.
(Schiess et al, 1999). We found a predominance (84.3%; 32/38 cells) of Type A neurons (little
or no spike-frequency accommodation upon depolarization) and less (14.7%; 6/38 cells) of Type
B neurons (showing accommodation) in our recorded neuronal population. Our cell typing
analysis does not reveal any significant difference in the effect of nociceptin on membrane
characteristics of both cell types (Supp. Fig. 1A and B), suggesting that this peptide may act
independently on both cell types. Nociceptin also did not alter the number of action potentials
upon depolarization (Suppl. Fig. 1C and D) in either Type A or Type B cells. It must be noted
that the synaptic responses elicited by local stimulation appeared similar across all neuronal
types regardless of firing properties.
Supplementary Figure 1. Nociceptin has similar effects in both Type A and Type B
neurons. Based on the electrophysiological characteristics ascribed by Schiess et al., (Schiess et
al, 1999), we divided our CeA neuronal population into Type A (n=32) and Type B (n=6)
neurons. A-B) I-V curves show that superfusion of nociceptin (500 nM) does not change the
resting membrane potential in either Type A or Type B CeA neurons. C-D) In both Type A and
Type B neurons, there is no alteration of the number of action potentials after 500 nM nociceptin
superfusion. The number of actions potentials for Type A neurons in response to 200 and 400 pA
current injection were: 4.25±0.6 and 8.95±0.8, respectively, during control recording and
4.35±0.7 and 8.85±0.8 during nociceptin superfusion. The number of actions potentials for Type
B neurons in response to 200 and 400 pA current injection were: 3.5±0.6 and 5.4±0.8,
respectively, during control recording and 3.25±0.8 and 5.6±0.9 during nociceptin superfusion.
E-F) Representative current clamp recordings of Type A (left) and Type B (right) neurons during
control (top) and nociceptin superfusion (bottom). Nociceptin did not significantly affect the
firing pattern or number of action potentials in our CeA neuronal population.
Supplementary Figure 2. Effects of nociceptin and ethanol at CeA synapses. Schematic
diagram of a CeA GABAergic synapse and glutamatergic afferent, including presynaptic
nociceptin receptors (NOP) that modulate neurotransmitter release and postsynaptic ionotropic
receptors located at synapses. A) In the CeA synapse of an ethanol-naïve rat, the predominant
presynaptic effect of acute alcohol is increased GABA release. Acute ethanol enhances GABA
release from afferents and/or interneurons and inhibits postsynaptic glutamate receptors. Thus,
acute ethanol increases the inhibition of CeA projection neurons, leading to excitation (i.e.,
disinhibition) of downstream (e.g., BNST) neurons. Activation of presynaptic NOP receptors
reduces GABA and glutamate release onto CeA inhibitory projection neurons, and inhibits
postsynaptic glutamate receptors. This occlusion of the ethanol effects on both the GABA and
glutamate systems by nociceptin/NOP decreases the inhibition of the CeA projecting neurons to
inhibit the downstream targets (e.g., increasing GABA release in BNST). B) Following chronic
alcohol exposure (i.e., the development of alcohol dependence), the net release of GABA is
increased at CeA synapses. This increased GABA release may be due to increased number
and/or function of CRF1 receptors (not shown in the schematic, see (Roberto et al, 2010b)) in the
CeA. There is also evidence for increased number and/or function of presynaptic NOP only on
the GABAergic terminals. Activation of presynaptic NOP receptors induces a larger decrease in
the release of GABA, but not glutamate, onto CeA inhibitory projection neurons, and still blocks
the ethanol effects on both GABA and glutamate levels, thus further increasing the inhibition of
downstream targets (e.g., BNST).
References Cited
Cruz MT, Herman MA, Cote DM, Ryabinin AE, Roberto M (2013). Ghrelin increases
GABAergic transmission and interacts with ethanol actions in the rat central nucleus of the
amygdala. Neuropsychopharmacology 38(2): 364-375.
Cruz MT, Herman MA, Kallupi M, Roberto M (2012). Nociceptin/orphanin FQ blockade of
corticotropin-releasing factor-induced gamma-aminobutyric acid release in central amygdala is
enhanced after chronic ethanol exposure. Biol Psychiatry 71(8): 666-676.
Gilpin NW, Henderson AN, Badia-Elder NE, Stewart RB (2011). Effects of neuropeptide Y and
ethanol on arousal and anxiety-like behavior in alcohol-preferring rats. Alcohol 45(2): 137-145.
Haubensak W, Kunwar PS, Cai H, Ciocchi S, Wall NR, Ponnusamy R, et al (2010). Genetic
dissection of an amygdala microcircuit that gates conditioned fear. Nature 468(7321): 270-276.
Herman MA, Contet C, Justice NJ, Vale W, Roberto M (2013a). Novel subunit-specific tonic
GABA currents and differential effects of ethanol in the central amygdala of CRF receptor-1
reporter mice. J Neurosci 33(8): 3284-3298.
Herman MA, Kallupi M, Luu G, Oleata CS, Heilig M, Koob GF, et al (2013b). Enhanced
GABAergic transmission in the central nucleus of the amygdala of genetically selected
Marchigian Sardinian rats: Alcohol and CRF effects. Neuropharmacology 67: 337-348.
Roberto M, Cruz M, Bajo M, Siggins GR, Parsons LH, Schweitzer P (2010a). The
endocannabinoid system tonically regulates inhibitory transmission and depresses the effect of
ethanol in central amygdala. Neuropsychopharmacology 35(9): 1962-1972.
Roberto M, Cruz MT, Gilpin NW, Sabino V, Schweitzer P, Bajo M, et al (2010b). Corticotropin
Releasing Factor-Induced Amygdala Gamma-Aminobutyric Acid Release Plays a Key Role in
Alcohol Dependence. Biol Psychiatry(67(9)): 831-839.
Roberto M, Madamba SG, Moore SD, Tallent MK, Siggins GR (2003). Ethanol increases
GABAergic transmission at both pre- and postsynaptic sites in rat central amygdala neurons.
Proc Natl Acad Sci U S A 100(4): 2053-2058.
Roberto M, Madamba SG, Stouffer DG, Parsons LH, Siggins GR (2004a). Increased GABA
release in the central amygdala of ethanol-dependent rats. J Neurosci 24(45): 10159-10166.
Roberto M, Schweitzer P, Madamba SG, Stouffer DG, Parsons LH, Siggins GR (2004b). Acute
and chronic ethanol alter glutamatergic transmission in rat central amygdala: an in vitro and in
vivo analysis. J Neurosci 24(7): 1594-1603.
Roberto M, Siggins GR (2006). Nociceptin/orphanin FQ presynaptically decreases GABAergic
transmission and blocks the ethanol-induced increase of GABA release in central amygdala. Proc
Natl Acad Sci U S A 103(25): 9715-9720.
Rogers J, Wiener SG, Bloom FE (1979). Long-term ethanol administration methods for rats:
advantages of inhalation over intubation or liquid diets. Behav Neural Biol 27(4): 466-486.
Schiess MC, Callahan PM, Zheng H (1999). Characterization of the electrophysiological and
morphological properties of rat central amygdala neurons in vitro. J Neurosci Res 58(5): 663673.
Van der Kloot W (1991). The regulation of quantal size. Prog Neurobiol 36(2): 93-130.